by The plasmid DNA manufacturing market involves the production of plasmids that are used as therapeutic agents, especially in gene therapy and DNA vaccination. Plasmid DNA is a small, circular, double-stranded piece of DNA that occurs naturally in bacteria and is commonly used in molecular cloning. Plasmids used in gene therapy and DNA vaccines contain genes that produce therapeutic proteins. They help tackle several genetic disorders and diseases by delivering therapeutic genes directly into the cells and tissues. Growing demand for gene and cell therapy for treating cancer, genetic disorders, infectious diseases, and other conditions is fueling growth in the plasmid DNA manufacturing market.
The Global plasmid DNA manufacturing market Size is estimated to be valued at US$ 1038.19 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2030.
Key Takeaways
Key players: Key players operating in the Plasmid DNA manufacturing are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG among others. These players are focusing on capacity expansion to meet the growing demand.
Growing demand: There is growing demand for plasmid DNA for gene and cell therapy applications owing to the rising prevalence of cancer and genetic disorders. Plasmid DNA helps in delivery of therapeutic genes directly into cells and tissues for treatment of various diseases.
Global expansion: Major players in the market are expanding their production facilities globally especially in North America and Europe to facilitate clinical trials and commercialization of gene and cell therapy products. For example, Aldevron expanded its production facility in Europe.
Market key trends: One of the key trends in the plasmid DNA manufacturing market is technological advancements in DNA construction and production methods. Companies are focusing on developing improved methods like Gibson assembly for higher yields and consistency in plasmid DNA production. Automation of upstream and downstream processes is another trend to enhance manufacturing efficiencies.
Porter’s Analysis
Threat of new entrants: The threat of new entrants into the plasmid DNA manufacturing market is moderate. High capital investment requirement and expertise in handling sensitive genetic material pose an entry barrier for new players.
Bargaining power of buyers: The bargaining power of buyers in the plasmid DNA manufacturing market is high. Large pharmaceutical and biotech companies have significant negotiation power due to their high volume purchases and alternative bargaining methods.
Bargaining power of suppliers: The bargaining power of suppliers is moderate. Key raw materials like high-quality bacteria and enzymes used in plasmid DNA manufacturing have few substitutes. However, established supplier relationships maintain steady supply.
Threat of new substitutes: The threat of substitutes is low. No alternative method offers the quality, precision and scalability of plasmid DNA manufacturing process.
Competitive rivalry: The competitive rivalry in the market is high owing to presence of numerous global players offering innovative technologies and value-added services. Players compete on quality, reliability, capacity and pricing to gain market share.
Geographical Regions
North America region accounted for the major share in the plasmid DNA manufacturing market in terms of value in 2024. This is attributed to presence of key market players, growing biopharmaceutical industry and increasing research funding in the region.
Asia Pacific region is expected to witness the fastest growth during the forecast period from 2024 to 2030. This is owing to factors such as expanding biotech industry, low manufacturing costs, development of new vaccines and increasing outsourcing of plasmid DNA manufacturing activities to China and India.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
